2014 in review – NICE

Michael Wonder - January 2015

www.maestrodatabase.com

NICE issued 26 Final Appraisal Determinations (FADs) in 2014; these are summarised below.

• ·    Two of the 26 FADs were for a device, one was for a procedure and the rest were for medicines
• ·      All bar three were associated with a recommendation; two were not recommended and a decision could not be made on the other technology because its sponsor did not lodge a submission
• ·      11 FADs were for a new medicine of which three are for patients with one disease (multiple sclerosis)
• ·      11 FADs were for a technology used to treat patients with cancer

Final Appraisal Determinations issued by NICE in 2014

Month	Medicine	Disease/condition	Sponsor	NICE outcome
January	Teriflunomide (Aubagio)	Multiple sclerosis	Genzyme	Recommended
February	Replacement prostheses	Hip disease	Various	Recommended
	Aflibercept (Eylea)	Macular oedema	Bayer	Recommended
	Pixantrone dimaleate (Pixuvri)	Non-Hodgkin's lymphoma	Cell Therapeutics	Recommended
March	Aflibercept (Zaltrap)	Colorectal cancer	Sanofi	Not recommended
	Rituximab (MabThera)	Antibody –associated vasculitis	Roche	Recommended
April	Pemetrexed disodium heptahydrate (Alimta)	Non small-cell lung cancer	Eli Lilly	Not recommended
	Afatinib dimaleate (Giotrif)	Non small-cell lung cancer	Boehringer Ingelheim	Recommended
	Bortezomib (Velcade)	Multiple myeloma	Janssen-Cilag	Recommended
May	Alemtuzumab (Lemtrada)	Multiple sclerosis	Genzyme	Recommended
	Ustekinumab (Stelara)	Psoriatic arthritis	Janssen-Cilag	Not recommended
June	Cardiac resynchronisation	Heart failure	Various	Recommended
	Canagliflozin hemihydrate (Invokana)	Type 2 diabetes mellitus	Janssen-Cilag	Recommended
July	Enzalutamide (Xtandi)	Prostate cancer	Astellas	Recommended
	Prasugrel hydrochloride (Efient)	Acute coronary syndrome	Eli Lilly	Recommended
	Lubiprostone (Amitiza)	Constipation	Sucampo	Recommended
	Ipilimumab (Yervoy)	Malignant melanoma	BMS	Recommended
August	Dimethyl fumarate (Tecfidera)	Multiple sclerosis	Biogen Idec	Recommended
September	Nil
October	Dabrafenib mesylate (Tafinlar)	Malignant melanoma	GSK	Recommended
November	Lenalidomide (Revlimid)	Myelodysplastic syndromes	Celgene	Recommended
	Erythropoiesis stimulating agents	Anaemia	Various	Recommended
	Dual chamber pacemakers	Bradycardia	Various	Recommended
	Nalmefene hydrochloride dehydrate (Selincro)	Alcohol dependence	Lundbeck	Recommended
	Imatinib mesylate (Glivec)	Gastro-intestinal stromal tumour	Novartis	Recommended
December	Dabigatran etexilate mesylate (Pradaxa)	Venous thromboembolism	Boehringer Ingelheim	Recommended
	Idelalisib (Zydelig)	Non-Hodgkin's lymphoma	Gilead	No outcome

© Wonder Drug Consulting Pty Ltd, 2015.